+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2022

  • PDF Icon

    Report

  • 312 Pages
  • August 2022
  • Region: Global
  • BioInformant
  • ID: 5313562

Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The cargo contained within exosomes can offer prognostic information for a range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer.  Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient’s response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

The Era of Exosomes

For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to credit exosomes for a range of promising traits.

When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term “exosome” is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.

To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.

Globally, there are at least 204 clinical trials focusing on exosome-related studies. Of these, 114 trials are evaluating exosome-based therapeutics and 74 trials are testing exosome-based diagnostic tests. Currently, 93 of the exosome trials (45%) are observational studies and 111 of them (55%) are interventional studies. The exosome industry has also achieved two approvals of FDA-approved diagnostic tests: Bio-Techne’s ExoDx Prostate IntelliScore Test for prostate cancer and Guardant’s 360 CDx test for non-small cell lung cancer.

Exosome Market Forces

To characterize the rapidly expanding exosome market, the publisher has released a 312-page global market report that explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials.

It highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 118 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2028.

Today the exosome industry is witnessing:

  • A surging number of scientific papers investigating exosomes and their applications
  • Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
  • Swelling appetite among investors for exosome technology
  • An increasingly competitive IP environment
  • A diverse range of co-development partnerships
  • Proliferating numbers of exosome competitors in all major life science markets worldwide
  • This global strategic report about the exosome industry reveals:
  • The clinical pipeline for exosome therapeutics
  • Clinical trial activity by type, region, phase, and sponsor
  • Exosome industry events, including M&A activity, financing events, and IPOs
  • Strategic partnerships and co-development agreements
  • Competitors composing the global marketplace, including core technologies and products under development
  • Market size determinations by market segment, with forecasts through 2030
  • Exosome industry trends, competitive opportunities, and future directions.

Table of Contents

1.    REPORT OVERVIEW
1.1    Statement of the Report
1.2    Target Demographic
1.3    Report Sources
1.4    Purpose of the Report
1.5    Executive Summary
1.6    Introduction

2.    EXOSOMES: AN OVERVIEW
2.1    Structure of an Exosome
2.1.1     Molecular Contents of Exosomes
2.1.1.1     Proteins in Exosomes
2.1.1.2     Lipid Contents of Exosomes
2.1.1.3     Nucleic Acids in Exosomes
2.1.2     Components of Membrane and Lumen of Exosomes
2.2    Classification of Exosomes
2.2.1     Natural Exosomes
2.2.1.1     Isolation of Natural Exosomes
2.2.2     Modified Exosomes
2.2.2.1     Types of Therapeutic Cargo used in Exosome Modifications
2.2.3     Synthetic Exosomes
2.3    Biomedical Applications of Engineered Exosomes
2.4    Functions of Exosomes
2.4.1     Pivotal Role of Exosomes
2.4.2     Adaptability to Engineering
2.5    Differences between Exosome Therapy and Cell Therapy
2.6    Sources of Exosomes for Research
2.7    Leveraging Exosomes as Biomarkers
2.8    The Shift from Cell Therapy to Exosome Therapy

3.    EXOSOME ENGINEERING: THE NEW PLATFORM
3.1    Interior Modification
3.1.1     Pre-Isolation Interior Modification Methods
3.1.1.1     Incubation
3.1.1.2     Gene Editing
3.1.2     Post-Isolation Interior Modification Methods
3.2    Surface Modifications
3.2.1     Surface Modification through Parent Cells
3.2.2     Direct Surface Modification
3.2.3     Loaded and Displayed Molecules in Direct Exosome Engineering
3.3    Comparison of Modification Methods
3.4    Clinical Applications of Designer Exosomes
3.4.1     Targeted Designer Exosomes
3.4.2     Anti-Cancer Designer Exosomes
3.4.3     Regenerative Designer Exosomes
3.5    Companies Developing Engineered Exosome-Based Therapeutics

4.    MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE
4.1    Cardiovascular Diseases
4.2    Kidney Diseases
4.3    Liver Diseases
4.4    Wound Healing
4.5    MSC Exosome-Based Clinical Trials for Regenerative Medicines

5.    EXOSOME RESEARCH
5.1    Research to Inhibit Disease-Derived Exosomes
5.1.1     Research to use Exosomes as Therapeutic Platforms
5.1.2     Research to use Exosomes as Carriers of Genes in Gene Therapy
5.1.3     Research to use Exosomes as Drug Delivery Vehicles
5.1.4     Research to Develop Technologies for Exosome Isolation
5.2    Common Isolation Methods in Exosome Research
5.3    Quality Control (QC) of Exosomes in Exosome Research
5.4    Bioimaging Modalities used in Exosome Research
5.5    Labeling Methods used in Exosome Research
5.5.1     Fluorescent Dyes used in Labeling Exosomes
5.5.2     Common Methods to Remove Unlabelled Probes
5.6    Determination of Exosome Dose in Exosome Studies
5.7    Routes of Exosome Administration
5.8    Characterization of Exosomes in Research

6.    COMMERCIALLY AVAILABLE EXOSOME RESEARCH TOOLS
6.1    Exosome Capture/Quantification Kits
6.1.1     Exosome-associated RNA Isolation Kits
6.2    Exosome Standards
6.3    Immunoplates for Capturing Exosomes
6.4    Immunobeads for Exosome Isolation
6.5    Exosome Marker Antibodies

7.    SCIENTIFIC PUBLICATIONS IN EXOSOMES
7.1    Trends in Global Publications
7.1.1     PubMed Publications on Exosome DNA as Diagnostics
7.1.2     Number of PubMed Publications on Exosome RNA as Diagnostics
7.1.3     PubMed Publications on Exosome Proteins as Diagnostics
7.1.4    PubMed Publications on Exosomes Derived from Stem Cells
7.1.5     PubMed Publications on Exosome-based Diagnostics
7.1.6     PubMed Publications on Exosome-based Therapeutics
7.1.7     PubMed Publications on Exosomes for Cancer Diagnosis
7.1.8     PubMed Publications on Exosomes for Pregnancy Disorders Diagnosis
7.2    Future in Exosome Research Publications

8.    EXOSOME PATENT LANDSCAPE
8.1    A Brief Overview of Current Exosome Patent Landscape
8.1.1     Patents/Patent Applications Relevant to Exosome-Sources
8.1.2     Patents/Applications Related to Exosomes-Isolation/Preparation
8.1.3     Patents/Applications Related to Type of Cargo
8.1.4     Patents/Applications Related to Cargo Loading Methods
8.1.5     Patents/Applications Related to Therapy Area
8.2    Leading Assignees of Exosome Patents
8.2.1     Types of Patented Isolation/Preparation Technologies by Assignees
8.2.2     Types of Cargos Employed by Assignees
8.2.3     Cargo Loading Methods by Assignees
8.2.4    Therapy Areas by Assignees
8.3    Exosome Patent/Patent Applications by Geography
8.4    Legal Status of Exosome Patent/Patent Applications
8.5    Assignee Categories

9.    EXOSOMES: CLINICAL TRIAL LANDSCAPE
9.1    Sources of Exosomes used in Clinical Trials
9.2    Studies using Anti-Tumor Antigens
9.3    Studies using Cytotoxic Drugs against Cancer
9.4    Recruitment Status of Ongoing Exosome-based Clinical Trials
9.5    Study Designs
9.6    Study Phases
9.7    Funding Types
9.8    Exosome Clinical Trials by Geography
9.9    Clinical Trials Involving MSC-Derived Exosomes
9.10    Examples of Clinical Trials involving Drug-Loaded Exosomes

10.    CURRENT STATUS OF EXOSOME MANUFACTURING
10.1    Production of Exosomes from Cell Cultures
10.2    Production Formats
10.2.1     Large Scale Production
10.2.1.1    Upstream Cell Line Production
10.2.1.2    Downstream Exosome Purification Methods
10.3    Companies Offering Exosome-Related Services

11.    EXOSOME ISOLATION APPROACHES
11.1    Differential Ultracentrifugation
11.1.1     Gradient Density Ultracentrifugation
11.2    Ultrafiltration & Sequential Ultrafiltration
11.3    Size-exclusion Chromatography
11.4    Polymer Precipitation
11.5    Immunoaffinity Capture
11.6    Microfluidics-Based Techniques
11.6.1     Active and Passive Methods of Microfluidics-based Platforms
11.7    Commercially Available Exosome Isolation Kits
11.7.1     Comparison of Currently used Exosome Isolation Techniques
11.7.2     Quality of Exosomes Isolated by Different Methods
11.8    Summary of Different Exosome Isolation Methods
11.9    Characterization of Exosomes
11.9.1     Size and Shape
11.9.2     Molecular Profiling
11.9.3     Proteomics and Lipidomics
11.9.4     Genomics
11.10    Microscopy and Nanoscopy for Exosome Imaging
11.11    Direct Post-Isolation Labeling for Imaging
11.12    Approaches for Exosome Analysis for Gene and Protein Biomarkers
11.13    Emerging Optical Technologies for Exosome Analysis
11.14    Emerging Electrochemical and Electromechanical Approaches

12.    DIAGNOSTIC APPLICATIONS OF EXOSOMES
12.1.1     Exosomal Proteins as Diagnostic Biomarkers
11.1.2     Exosomal Nucleic Acids as Biomarkers
12.1.3     Non-Coding RNAs in Exosomes as Biomarkers in Cancers
12.1.3.1    Exosomes from other Biofluids as Biomarkers for Cancer
12.2    Exosome Biomarkers in Pregnancy Disorders
12.3    Exosome Biomarkers and Early Diagnosis of Immunologic Rejection
12.4    Number of PubMed Articles on Exosome-Based Diagnosis
12.5    Clinical Trials involving Exosome-based Diagnostics

13.    THERAPEUTC APPLICATIONS OF EXOSOMES
13.1    Advantages of Exosomes as Therapeutics
13.2    Therapeutic Exosome Platforms
13.2.1     Naïve Exosome Therapeutics
13.2.2     Engineered Exosome Therapeutics
13.2.2.1    Passive Cargo Loading
13.2.2.2    Active Cargo Loading
13.3    Drugs Encapsulated in Exosomes
13.4    Preclinical Studies involving Loaded Exosome Therapeutics
13.5    Clinical Trials involving Exosome Therapeutics

14.    APPLICATION OF EXOSOMES IN VACCINE DEVELOPMENT
14.1    Exosome-Based Immunotherapy in Animal Models
14.2    Ongoing Clinical Trials Involving Exosomes in Developing Vaccines

15.    CURRENT STATUS OF EXOSOME INDUSTRY
15.1    The Shift from Cell Therapy to Exosome Therapy
15.2    Clinical Applications of Exosomes
15.2.1     Diagnostic Applications
5.2.2     Approved Exosome Diagnostics
15.2.2.1     ExoDx Prostate IntelliScore (EPI) Test
15.2.2.2     Guardant360 CDx
15.3    Clinical Trials Focusing on Exosome-Based Diagnostics
15.4    Therapeutic Applications of Exosomes
15.4.1     Promising Exosome-Based Therapeutic Candidates
15.4.1.1     AB 126
15.4.1.2    AGLE-102
15.4.1.3    AVA-201
15.4.1.4    AVA-202
15.4.1.5    AZ001
15.4.1.6    CAP-2003
15.4.1.7    exoIL-12
15.4.1.8    ExoPr0
15.4.1.9    exoSTING
15.4.1.10    Plexaris
15.4.1.11    UNEX-42
15.4.1.12    Unexisome
15.5    Addreseable Diseases by Exosome Therapeutic Candidates
15.6    Exosome-Based Vaccine Development
15.7    Current Status of Exosome-Based Clinical Trials
15.8    NIH Funding for Exosome Research
15.9    Deals and Fund Raising in Exosome Space
15.9.1     Partnership Deals within Exosome Space
15.9.1.1    Exopharm and Astellas
15.9.1.2    Univercells Technologies and RoosterBio
15.9.1.3    AgeX Therapeutics and UCI
15.9.1.4    VivaZome and La Trobe University
15.9.1.5    Evotec SE and Curexsys GmbH
15.9.1.6    Bio-Techne and QIAGEN
15.9.1.7    InnoCan Pharma and Recipharms
15.9.1.8    Sarepta Therapeutics and Codiak Biosciences
15.9.1.9    Navigo Proteins and MDimune
15.9.1.10    Evox Therapeutics and Takeda
15.9.1.11    Jazz Pharmaceuticals and Codiak Biosciences
15.9.1.12    PureTech Health and Roche
15.9.1.13    Exosome Diagnostics and Intezyne
15.9.1.14    Evox Therapeutics and Boehringer Ingelheim
15.9.2     Acquisition Deals
15.9.2.1    Lonza’s Acquisition of Exosomics
15.9.2.2    Lonza and Codiak Biosciences
15.9.2.3    Bio-Techne and Exosome Diagnostics
15.9.2.4    Lonza and HansaBioMed
15.9.3     Licensing Deals
15.9.3.1    Evox Therapeutics and Eli Lilly
15.9.3.2    VivaZome Therapeutics and University of Adelaide
15.9.3.3    CEVEC and Evox Therapeutics
15.9.3.4    Orgenesis and Excella Bio
15.9.4     Fund Raising in Exosome Space
15.9.4.1    Series C Financing Round by Evox Therapeutics
15.9.4.2    Series B Financing Round for ILIAS Biologics
15.9.4.3     Initial Public Offering (IPO) by Codiak Biosciences
15.9.4.4     Series C Funding for ExoCoBio
15.9.4.5     Common Stock Financing by ArunA Bio
15.9.4.6     Early-Stage Award for Evox Therapeutics
15.9.4.7     Series A Funding for ExoCoBio
15.9.4.8     NIH Grant for Capricor
15.10    Current Industry Leaders in Exosome Sector
15.10.1     ArunA Biomedical
15.10.2     Capricor Therapeutics
15.10.3     Codiak Biosciences
15.10.4     Evox Therapeutics
15.10.5     Exosome Diagnostics, Inc (Bio-Techne)
15.10.6     Exocyte Therapeutics
15.10.7     Kimera Labs
15.10.8     NanoSomiX
15.11    The Four Categories of Exosome Companies
15.12    Current Exosome Technologies by Commercial Companies
15.12.1     Brief Descriptions of Major Exosome Technologies and Companies
15.12.1.1    AGLE-102 from Aegle Therapeutics
15.12.1.2    CDC Exosomes from Capricor Therapeutics
15.12.1.3    engEX Platform from Codiak Biosciences
15.12.1.4    DeliverEX from Evox Therapeutics
15.12.1.5    Exo-101 from Exogenus Therapeutics
15.12.1.6    Hybridozome from Anjarium Biosciences
15.12.1.7    Neuronal Exosomes from Aruna Bio
15.12.1.8    ExoPro from ReNeuron
15.12.1.9    Plexaris from Exopharm Pty., Ltd.
15.12.1.10    ExoSCRT from ExoCoBio

16.    EXOSOME MARKET ANALYSIS
16.1    Market for Exosome Therapeutics
16.2    The Market for Exosome Diagnostics
16.3    Market for Exosome Research Products
16.3.1     Market Shares for Exosome Isolation Tools
16.3.2     Percent Utilization of Research Tools used on Captured Exosomes

17.    PROFILES OF EXOSOME MARKET COMPETITORS
17.1  101 Bio
17.1.1     Exosome Services
17.2    Abbexa, Ltd.
17.3    Abnova
17.4    Adipomics, Inc.
17.5    Aegle Therapeutics
17.5.1     Extracellular Vesicle Therapy
17.6    AgeX Therapeutics
17.6.1     PureStem Technology
17.6.2     Induced Tissue Regeneration
17.6.3     UniverCyte
17.6.4     HyStem Delivery Technology
17.7    Aethlon Medical, Inc.
17.7.1     Homopurifier
17.8    Ambiotech
17.9    AMS Biotechnology, Ltd. (AMSBIO)
17.9.1     Products
17.10    Anjarium Biosciences
17.10.1     Anjarium’s Hybridosome Platform
17.11    Antibodies-Online GmbH
17.12    Aposcience AG
17.12.1     Wound Healing
17.12.2     Myocardial Infarction
17.13    Aruna Bio
17.13.1     AB126
17.14    Avalon GloboCare Corp.
17.14.1     Avalon’s Core Platforms
17.15    Aviva Systems Biology
17.16    Azymus Therapeutics
17.16.1     AZ Platform
17.17    Beckman Coulter Life Sciences
17.17.1     Optima XPN
17.17.2     Vi-CELL BLU - Cell Viability Analyzer
17.17.3     SW 32 Swinging Bucket Rotor
17.17.4     CytoFLEX - Flow Cytometer
17.18    BioCat GmbH
17.18.1     Exosome Purification Kits
17.19    BioFluidica
17.20    Biological Dynamics, Inc.
17.20.1     Verita Isolation Platform
17.21    Biorbyt, Ltd.
17.22    BioRegenerative Sciences, Inc.
17.22.1     SRM Technology
17.23    Bio-Techne
17.23.1     Products
17.24    BioVision, Inc.
17.25    BrainStorm Cell Therapeutics
17.25.1     Exosomes for COVID-19
17.26    BreStem Therapeutics, Inc.
17.27    Capricor Therapeutics
17.27.1     Exosome Program
17.28    Carmine Therapeutics
17.29    CD Bioparticles
17.29.1     Exosome Services
17.30    Cellarcus Biosciences, Inc.
17.30.1     vFC Vesicle Analysis Assays
17.30.2     vTag Antibodies
17.30.3     Vesicles and Vesicle Standards
17.30.4     Vesicle Analysis Services
17.30.5     Measuring EV Size and Concentration
17.30.6     Quantifying Vesicle Cargo
17.30.7     Custom Analysis Services
17.31    Cell Care Therapeutics
17.31.1     CCT-101
17.32    Cell Factory BVBA/Esperite NV
17.32.1     Exosome Projects
17.33    Cell Guidance Systems, Ltd.
17.33.1     Exosomes from Cell Guidance
17.33.2     Exo-Spin Exosome Purification
17.33.3     Exosome Characterization
17.33.4     ExoLISA Technology: Exosome Detection
17.33.5     NTA Size Profiling Service
17.34    Ciola
17.34.1     Exosome Customization Technology
17.35    CK-Exogene
17.36    Clara Biotech
17.36.1     ExoRelease
17.37    Codiak Biosciences
17.37.1     engEx Platform
17.37.2     Pipeline Products
17.37.2.1    exoSTING
17.37.2.2    exolL-12
17.37.2.3     exoASO-STAT6
17.38    Coya Therapeutics, Inc.
17.39    Craif, Inc.
17.39.1     Nanowire Device
17.40    Creative Bioarray
17.41    CreativeBiostructure
17.42    Creative Biolabs
17.42.1     Products
17.42.2     Services
17.43    Creative Medical Technology Holdings
17.43.1     AmnioStem Stroke Therapy
17.44    Creative Proteomics
17.44.1     Exosome Proteomics Services
17.45    Curexsys GmbH
17.45.1     Technology
17.46    CUSABIO TECHNOLOGY LLC
17.46.1     Exosome Isolation Kits
17.47    Diadem Biotherapeutics
17.47.1     Technology
17.48    Direct Bio
17.48.1     ExoFlo
17.48.2     AmniWrap
17.49    DLdevelop
17.50    Entelexo Biotherapeutics
17.51    EverZom
17.51.1     Services
17.52    Evomic Science LLC
17.52.1     ExoEZ Exosome Isolation Kit
17.53    Evora Biosciences SAS
17.54    Evox Therapeutics, Ltd.
17.54.1     Protein Therapeutics
17.54.2     RNA Therapeutics
17.55    ExBiome BV
17.55.1     ExomiR Technology
17.56    Exrkine Corp.
17.57    ExoCan Healthcare Technologies, Pvt. Ltd.
17.57.1     ExoEnrich Exosome Isolation Kit
17.57.2     ExoEngineering
17.58    ExoCoBio, Co., Ltd.
17.58.1     Products
17.59    Exogenus Therapeutics
17.60    ExoPERT
17.60.1     EXo-i
17.61    ExoPharm
17.61.1     LEAP Technology
17.61.2     Cevaris & Plexaris
17.61.3     Partnering Strategy
17.61.3.1    Exosome Technologies
17.61.3.2    Exosome Medicines
17.62    ExosomeDx (biotechne)
17.62.1     ExoDX Prostate Test
17.62.2     Pharma Services
17.63    ExosomePlus
17.64    Exosome Sciences
17.64.1     TauSome Biomarker
17.65    Exosomics S.p.A
17.65.1     ExoRef
17.65.2     SeleCTEV-DNA Enrichment Kits
17.65.3     SoRTEV-RNA Enrichment Kits
17.65.4     evGAG
17.66    ExoVectory
17.66.1     EVY-101
17.67    Florica Therapeutics
17.68    GenWay Biotech, Inc.
17.69    HansaBioMed Lifesiences, Ltd.
17.69.1     Products
17.70    ILIAS Biologics, Inc.
17.70.1     EXPLOR
17.70.2     Exo-Target
17.71    Innocan Pharma
17.71.1     CBD-Loaded Exosomes
17.72    Innovex Therapeutics, S.L
17.72.1     Research & Development
17.73    INOVIQ, Ltd.
17.73.1     EXO-NET (Research Use only)
17.74    Invent Biotechnologies, Inc.
17.75    Izon Science, Ltd.
17.75.1     qEV Isolation
17.76    Kimera Labs, Inc.
17.76.1     XoGlo
17.76.2     XoGlo Pro
17.76.3     Equisome HC
17.77    Leading Biology, Inc.
17.78    LifeSpan Biosciences, Inc.
17.79    Lonza Group, Ltd.
17.79.1     Exosome Service
17.80    Mantra Bio
17.80.1     Partnering
17.81    MDimune, Inc.
17.81.1     BioDrone Technology
17.82    Miltenyi Biotech B.V. and Co., KG
17.82.1     qEV Exosome Isolation Kit
17.83    miR Scientific
17.83.1     Prostate Cancer Test
17.84    Mursla, Ltd.
17.84.1     ExoPheno
17.85    MyBioSource, Inc.
17.86    NanoSomics, Inc.
17.86.1     Technology
17.87    NanoView Biosciences
17.87.1     ExoView R200
17.87.2     ExoView R100
17.87.3     ExoView Tetraspanin Kits
17.87.4     ExoFlex Kits
17.88    NeurExo Sciences
17.88.1     Research & Development Programs
17.89    NeuroDex, Inc.
17.90    NurExone Biologic Ltd
17.91    New England Peptide, Inc.
17.91.1     ME- Kit for Exosome Isolation
17.92    Norgen Biotek Corp.
17.92.1     Services
17.93    Novus Biologicals, LLC
17.93.1     Exosome Research Tools
17.94    nRix Dx, Inc.
17.95    Oasis Diagnostics Corporation
17.95.1     Pure.SAL
17.96    OmniSpirant, Ltd.
17.96.1     Technology
17.97    Organicell
17.98    OriGene Technologies, Inc.
17.99    Paracrine Therapeutics, Pvt. Ltd.
17.100    QIAGEN
17.100.1    ExoEasy Maxi Kit
17.100.2    miRCURY Exosome Kits
17.100.3    miRCURY LNA miRNA Focus PCR Panels
17.101    ReNeuron
17.101.1    Exosome Platform
17.102    RION
17.102.1    Technology
17.103    RoosterBio, Inc.
17.103.1    RoosterCollect-EV
17.103.2    RoosterCollect EV Pro
17.103.3    RoosterCollect-EV-CC
17.103.4    EV Boost
17.104    Rosetta Exosome
17.106    System Biosciences, LLC
17.106.1    Exosome Research Products
17.106.2    Exosome Research Services
17.107    Tavec Pharma
17.107.1    Technology
17.107.2    Acquisition by Therillia
17.108    Theoria Science, Inc.
17.108.1    Technology: ExoScreen
17.109    Thermo Fisher Scientific
17.109.1    Exosome Products for Testing and Research
17.110    TransGen Biotech, Co., Ltd.
17.111    TriArm Therapeutics, Co., Ltd.
17.111.1    Exosome Engineering Platform
17.112    United Therapeutics Corp.
17.112.1    Unexisome
17.113    Versatope Therapeutics
17.113.1    VT-105
17.114    Vesigen Therapeutics, Inc.
17.114.1    Technology
17.115    VivaZome Therapeutics, Pvt. Ltd.
17.115.1    VivaZome’s Collaboration with ANU
17.115.2    VivaZome’s Collaboration with ReNerve
17.116    Xollent Biotech
17.116.1    Pipeline
17.117    XOStem, Inc.
17.118    YMAIR Genomics, LLC
17.118.1    Urine Biomarker Isolation Method
17.118.2    Ymatrix

Companies Mentioned

  • 101 Bio 
  • AB  
  • Abbexa, Ltd. 
  • Abnova 
  • Acquisition by Therillia 
  • Adipomics, Inc. 
  • Aegle Therapeutics 
  • Aethlon Medical, Inc. 
  • AgeX Therapeutics 
  • Ambiotech 
  • AmnioStem Stroke Therapy 
  • AmniWrap 
  • AMS Biotechnology, Ltd. (AMSBIO) 
  • Anjarium Biosciences 
  • Anjarium’s Hybridosome Platform 
  • Antibodies-Online GmbH 
  • Aposcience AG 
  • Aruna Bio 
  • Avalon GloboCare Corp. 
  • Avalon’s Core Platforms 
  • Aviva Systems Biology 
  • AZ Platform 
  • Azymus Therapeutics 
  • Beckman Coulter Life Sciences 
  • Bio-Techne 
  • BioCat GmbH 
  • BioDrone Technology 
  • BioFluidica 
  • Biological Dynamics, Inc. 
  • Biorbyt, Ltd. 
  • BioRegenerative Sciences, Inc. 
  • BioVision, Inc. 
  • BrainStorm Cell Therapeutics 
  • BreStem Therapeutics, Inc. 
  • Capricor Therapeutics 
  • Carmine Therapeutics 
  • CBD-Loaded Exosomes 
  • CCT-  
  • CD Bioparticles 
  • Cell Care Therapeutics 
  • Cell Factory BVBA/Esperite NV 
  • Cell Guidance Systems, Ltd. 
  • Cellarcus Biosciences, Inc. 
  • Cevaris Plexaris 
  • Ciola 
  • CK-Exogene 
  • Clara Biotech 
  • Codiak Biosciences 
  • Coya Therapeutics, Inc. 
  • Craif, Inc. 
  • Creative Bioarray 
  • Creative Biolabs 
  • Creative Medical Technology Holdings 
  • Creative Proteomics 
  • CreativeBiostructure 
  • Curexsys GmbH 
  • CUSABIO TECHNOLOGY LLC 
  • Custom Analysis Services 
  • CytoFLEX Flow Cytometer 
  • Diadem Biotherapeutics 
  • Direct Bio 
  • DLdevelop 
  • engEx Platform 
  • Entelexo Biotherapeutics 
  • Equisome HC 
  • EV Boost 
  • EverZom 
  • evGAG 
  • Evomic Science LLC 
  • Evora Biosciences SAS 
  • Evox Therapeutics, Ltd. 
  • EVY-  
  • ExBiome BV 
  • EXo-i 
  • EXO-NET (Research Use only) 
  • Exo-Spin Exosome Purification 
  • Exo-Target 
  • exoASO-STAT  
  • ExoCan Healthcare Technologies, Pvt. Ltd. 
  • ExoCoBio, Co., Ltd. 
  • ExoDX Prostate Test 
  • ExoEasy Maxi Kit 
  • ExoEngineering 
  • ExoEnrich Exosome Isolation Kit 
  • ExoEZ Exosome Isolation Kit 
  • ExoFlex Kits 
  • ExoFlo 
  • Exogenus Therapeutics 
  • ExoLISA Technology: Exosome Detection 
  • exolL- 
  • ExomiR Technology 
  • ExoPERT 
  • ExoPharm 
  • ExoPheno 
  • ExoRef 
  • ExoRelease 
  • Exosome Characterization 
  • Exosome Customization Technology 
  • Exosome Engineering Platform 
  • Exosome Isolation Kits 
  • Exosome Medicines 
  • Exosome Platform 
  • Exosome Products for Testing and Research 
  • Exosome Program 
  • Exosome Projects 
  • Exosome Proteomics Services 
  • Exosome Purification Kits 
  • Exosome Research Products 
  • Exosome Research Services 
  • Exosome Research Tools 
  • Exosome Sciences 
  • Exosome Service 
  • Exosome Services 
  • Exosome Technologies 
  • ExosomeDx (biotechne) 
  • ExosomePlus 
  • Exosomes for COVID- 
  • Exosomes from Cell Guidance 
  • Exosomics S.p.A 
  • exoSTING 
  • ExoVectory 
  • ExoView  
  • ExoView Tetraspanin Kits 
  • EXPLOR 
  • Exrkine Corp. 
  • Extracellular Vesicle Therapy 
  • Florica Therapeutics 
  • GenWay Biotech, Inc. 
  • HansaBioMed Lifesiences, Ltd. 
  • Homopurifier 
  • HyStem Delivery Technology 
  • ILIAS Biologics, Inc. 
  • Induced Tissue Regeneration 
  • Innocan Pharma 
  • Innovex Therapeutics, S.L 
  • INOVIQ, Ltd. 
  • Invent Biotechnologies, Inc. 
  • Izon Science, Ltd. 
  • Kimera Labs, Inc. 
  • Leading Biology, Inc. 
  • LEAP Technology 
  • LifeSpan Biosciences, Inc. 
  • Lonza Group, Ltd. 
  • Mantra Bio 
  • MDimune, Inc. 
  • ME- Kit for Exosome Isolation 
  • Measuring EV Size and Concentration 
  • Miltenyi Biotech B.V. and Co., KG 
  • miR Scientific 
  • miRCURY Exosome Kits 
  • miRCURY LNA miRNA Focus PCR Panels 
  • Mursla, Ltd. 
  • MyBioSource, Inc. 
  • Myocardial Infarction 
  • NanoSomics, Inc. 
  • NanoView Biosciences 
  • Nanowire Device 
  • NeurExo Sciences 
  • NeuroDex, Inc. 
  • New England Peptide, Inc. 
  • Norgen Biotek Corp. 
  • Novus Biologicals, LLC 
  • nRix Dx, Inc. 
  • NTA Size Profiling Service 
  • NurExone Biologic Ltd 
  • Oasis Diagnostics Corporation 
  • OmniSpirant, Ltd. 
  • Optima XPN 
  • Organicell 
  • OriGene Technologies, Inc. 
  • Paracrine Therapeutics, Pvt. Ltd. 
  • Partnering 
  • Partnering Strategy 
  • Pharma Services 
  • Pipeline 
  • Pipeline Products 
  • Products 
  • Prostate Cancer Test 
  • Protein Therapeutics  
  • Pure.SAL 
  • PureStem Technology 
  • qEV Exosome Isolation Kit 
  • qEV Isolation 
  • QIAGEN 
  • Quantifying Vesicle Cargo 
  • ReNeuron 
  • Research Development 
  • Research Development Programs 
  • RION 
  • RNA Therapeutics  
  • RoosterBio, Inc. 
  • RoosterCollect EV Pro 
  • RoosterCollect-EV 
  • RoosterCollect-EV-CC 
  • Rosetta Exosome 
  • SeleCTEV-DNA Enrichment Kits 
  • Services 
  • SoRTEV-RNA Enrichment Kits 
  • SRM Technology 
  • SW  Swinging Bucket Rotor 
  • System Biosciences, LLC 
  • TauSome Biomarker 
  • Tavec Pharma 
  • Technology 
  • Technology: ExoScreen 
  • Theoria Science, Inc. 
  • Thermo Fisher Scientific 
  • TransGen Biotech, Co., Ltd. 
  • TriArm Therapeutics, Co., Ltd. 
  • Unexisome 
  • United Therapeutics Corp. 
  • UniverCyte 
  • Urine Biomarker Isolation Method 
  • Verita Isolation Platform 
  • Versatope Therapeutics 
  • Vesicle Analysis Services 
  • Vesicles and Vesicle Standards 
  • Vesigen Therapeutics, Inc. 
  • vFC Vesicle Analysis Assays 
  • Vi-CELL BLU Cell Viability Analyzer 
  • VivaZome Therapeutics, Pvt. Ltd. 
  • VivaZome’s Collaboration with ANU 
  • VivaZome’s Collaboration with ReNerve 
  • VT-  
  • vTag Antibodies 
  • Wound Healing 
  • XoGlo 
  • XoGlo Pro 
  • Xollent Biotech 
  • XOStem, Inc. 
  • YMAIR Genomics, LLC 
  • Ymatrix 

Methodology

The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.

Input Sources

  • Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
  • Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
  • Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
  • Product Launch Announcements (Trade Journals, Google News)
  • Industry Events (Google News, Google Alerts, Press Releases)
  • Company News (SEC Filings, Investor Publications, Historical Performance)
  • Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
  • Interviews with Stem Cell Industry Leaders

Research & Analysis Methodologies

The publisher employs the following techniques for deriving its market research:

  • Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
  • Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
  • Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
  • Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
  • Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
  • Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
  • Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).
 

Loading
LOADING...